Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON , AUG. 29, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS (NYSE: DNA) TODAY RELEASED THE FOLLOWING NOTICE: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA OAKLAND DIVISION WEINING HU, DERIVATIVELY ON BEHALF OF GINKGO BIOWORKS HOLDINGS, INC., A DELAWARE CORPORATION,                              PLAINTIFF,                 VS.

GINKGO BIOWORKS ISSUES NOTICE OF SETTLEMENT OF SHAREHOLDER DERIVATIVE ACTIONS

SECAUCUS, N.J. , AUG. 25, 2025 /PRNEWSWIRE/ --QUEST DIAGNOSTICS (NYSE:DGX), A LEADING PROVIDER OF DIAGNOSTIC INFORMATION SERVICES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH DEVICE DESIGNATION FOR THE COMPANY'S HAYSTACK MRD TEST FOR IDENTIFYING MRD-POSITIVE PATIENTS WITH STAGE II COLORECTAL CANCER FOLLOWING CURATIVE-INTENT SURGICAL TREATMENT WHO MAY BENEFIT FROM ADJUVANT THERAPY IN ACCORDANCE WITH THERAPEUTIC PRODUCT LABELING.

FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION FOR HAYSTACK MRD CIRCULATING TUMOR DNA TEST FROM QUEST DIAGNOSTICS

BOSTON , AUG. 20, 2025 /PRNEWSWIRE/ --GINKGOBIOWORKS (NYSE: DNA), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THAT ITS DATAPOINTS OFFERING HAS ENTERED INTO A NEW STRATEGIC PARTNERSHIP WITH INDUCTIVE BIO AND TANGIBLE SCIENTIFIC TO MAKE AI-DRIVEN LAB-IN-THE-LOOP DRUG DISCOVERY BROADLY ACCESSIBLE ACROSS THE INDUSTRY. THE PARTNERSHIP AIMS TO DELIVER CAPABILITIES THAT PREVIOUSLY REQUIRED MASSIVE PLATFORM INVESTMENTS BY COMBINING HIGH-THROUGHPUT EXPERIMENTAL WORKFLOWS, STREAMLINED COMPOUND MANAGEMENT, AND PREDICTIVE CHEMISTRY AI MODELS INTO A SEAMLESS INTEGRATED SERVICE THAT COULD HELP SCIENTISTS DESIGN BETTER DRUGS WITH FEWER RESOURCES.

GINKGO DATAPOINTS, TANGIBLE SCIENTIFIC, AND INDUCTIVE BIO PARTNER TO DEPLOY AI-DRIVEN LAB-IN-THE-LOOP WORKFLOWS ACROSS THE BIOPHARMA INDUSTRY

SEASONED LIFESCIENCE EXECUTIVE TO SPEARHEAD GLOBAL GOTOMARKET STRATEGY AS GINKGO AUTOMATION SCALES EXTERNAL SALES ACROSS BIOPHARMA, TECHBIO, AND NEW SCIENCEDRIVEN MARKETS WHILE CONTINUING TO SUPPORT INTERNAL PROGRAMS. BOSTON , AUG. 12, 2025 /PRNEWSWIRE/ -- GINKGOBIOWORKS (NYSE: DNA), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THE APPOINTMENT OF BRIANO'SULLIVAN AS HEAD OF COMMERCIAL FOR GINKGO AUTOMATION.

GINKGO AUTOMATION APPOINTS BRIANO'SULLIVAN AS HEAD OF COMMERCIAL TO ACCELERATE EXTERNAL GROWTH

GINKGO PROVIDES AN UPDATE ON ITS RESTRUCTURING, INCLUDING ACHIEVEMENT OF ITS EXPANDED $250 MILLION COST SAVINGS TARGETS BOSTON , AUG. 7, 2025 /PRNEWSWIRE/ -- GINKGOBIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO"), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED ITS RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025. THE UPDATE, INCLUDING A WEBCAST SLIDE PRESENTATION WITH ADDITIONAL DETAILS ON THE SECOND QUARTER, AS WELL AS SUPPLEMENTAL FINANCIAL INFORMATION WILL BE AVAILABLE AT INVESTORS.GINKGOBIOWORKS.COM.

GINKGO BIOWORKS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

PRESENTATION AND Q&A SESSION SCHEDULED FOR POST-MARKET ON THURSDAY, AUGUST 7, 2025 BOSTON , JULY 31, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO"), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THAT IT PLANS TO HOST A PRESENTATION AND Q&A SESSION REVIEWING BUSINESS PERFORMANCE FOR THE SECOND QUARTER ENDED JUNE 30, 2025, ON THURSDAY, AUGUST 7, 2025, BEGINNING AT 5:30 P.M. ET. THE PRESENTATION DETAILS AND WEBCAST LINK WILL BE AVAILABLE ON GINKGO'S INVESTOR RELATIONS WEBSITE AT HTTPS://INVESTORS.GINKGOBIOWORKS.COM , AND A REPLAY WILL BE MADE AVAILABLE.

GINKGO BIOWORKS ANNOUNCES DATE OF SECOND QUARTER 2025 RESULTS PRESENTATION

GINKGO WILL BUILD A PLATFORM DRIVEN BY ITS RECONFIGURABLE AUTOMATION CARTS (RACS) TECHNOLOGY TO ENABLE EMSL'S OPEN-ENDED EXPLORATION OF BIOCONOMY-RELEVANT MICROBES BOSTON , JULY 30, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS (NYSE: DNA), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THAT THE ENVIRONMENTAL MOLECULAR SCIENCES LABORATORY (EMSL) AT PACIFIC NORTHWEST NATIONAL LABORATORY (PNNL), A LEADING U.S. DEPARTMENT OF ENERGY OFFICE OF SCIENCE USER FACILITY, HAS SELECTED GINKGO AUTOMATION TO DELIVER A STATE-OF-THE-ART AUTOMATED ANAEROBIC PHENOTYPING PLATFORM AT ITS RICHLAND, WASHINGTON CAMPUS. THIS PURCHASE MARKS A SIGNIFICANT STEP IN EMSL'S MISSION TO ADVANCE FUNDAMENTAL BIOLOGICAL RESEARCH SUPPORTING U.S. ENERGY PRODUCTION, ENSURING LEADERSHIP IN THE BIOECONOMY, AND ESTABLISHING CRITICAL MATERIALS SUPPLY-CHAIN RESILIENCE.

GINKGO TO DEPLOY MODULAR AUTOMATION TECHNOLOGY TO THE ENVIRONMENTAL MOLECULAR SCIENCES LABORATORY (EMSL) AT PACIFIC NORTHWEST NATIONAL LABS (PNNL) TO ACCELERATE MICROBIAL RESEARCH FOR THE BIOECONOMY

BOSTON , MAY 21, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS (NYSE: DNA, "GINKGO" OR THE "COMPANY"), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED THAT MARK DMYTRUK, THE COMPANY'S CHIEF FINANCIAL OFFICER, INTENDS TO RESIGN FROM HIS ROLE AT THE COMPANY ON MAY 30, 2025 TO ACCEPT A POSITION AT ANOTHER ORGANIZATION AND STEVEN COEN, CPA, THE COMPANY'S CHIEF ACCOUNTING OFFICER, WILL BECOME CHIEF FINANCIAL OFFICER, EFFECTIVE UPON MR. DMYTRUK'S RESIGNATION.

GINKGO BIOWORKS ANNOUNCES APPOINTMENT OF STEVEN COEN AS CHIEF FINANCIAL OFFICER

GINKGO PROVIDES AN UPDATE ON ITS RESTRUCTURING, INCLUDING PROGRESS TOWARDS ITS EXPANDED $250 MILLION COST SAVINGS TARGET GINKGO AND PARTNERS AWARDED $29 MILLION CONTRACT BY ARPA-H TO DEVELOP DISTRIBUTED MANUFACTURING OF ESSENTIAL MEDICINES USING WHEAT GERM CELL-FREE EXPRESSION SYSTEMS BOSTON , MAY 6, 2025 /PRNEWSWIRE/ --GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA, "GINKGO"), WHICH IS BUILDING THE LEADING PLATFORM FOR CELL PROGRAMMING AND BIOSECURITY, TODAY ANNOUNCED ITS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025. THE UPDATE, INCLUDING A WEBCAST SLIDE PRESENTATION WITH ADDITIONAL DETAILS ON THE FIRST QUARTER, AS WELL AS SUPPLEMENTAL FINANCIAL INFORMATION WILL BE AVAILABLE AT INVESTORS.GINKGOBIOWORKS.COM.

GINKGO BIOWORKS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

REPLACING ARTIFICIAL DYES WITH NATURAL COLORS HAS BECOME A NATIONAL PRIORITY, MOVED BY CONSUMER DEMAND, REGULATION, AND GOVERNMENTAL PRESSURE. ACHIEVING THIS MILESTONEBY INCREASING COLORING EFFICIENCY AND REDUCING COSTSCOULD UNLOCK NEW MARKET SEGMENTS THAT ARE NOT WELL-SUPPORTED BY CURRENT NATURAL FOOD COLORS.

PHYTOLON AND GINKGO BIOWORKS BOOST NATURAL FOOD COLORS BY HITTING FULL-PROJECT MILESTONE, NEARLY TRIPLING THE MANUFACTURING EFFICIENCY OF PHYTOLON'S INNOVATIVE COLORS

Ginkgo Bioworks Holdings, Inc.

DNA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Ginkgo Bioworks Holdings, Inc.

DNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DNA